Clinical Trials Directory

Trials / Completed

CompletedNCT04357184

BFRT for Severe Lower Extremity Muscle Atrophy

Blood Flow Restriction Training for Severe Lower Extremity Muscle Atrophy

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
100 (actual)
Sponsor
Cincinnati Sportsmedicine Research and Education Foundation · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Muscle weakness or atrophy is a common condition following acute and chronic musculoskeletal injuries. Strength training is an imperative component in clinical rehabilitation of musculoskeletal injuries. Heavy exercise loads (approximately 70% of one repetition maximum) is necessary to elicit muscle hypertrophy and strength gains. However, patients with severe muscle atrophy are frequently unable to tolerate these loads due to pain. Blood flow resistance training with low resistance loads may be used to safely develop muscle strength.

Detailed description

Blood flow restriction training (BFRT) is a safe type of low intensity resistance exercise that has demonstrated enhanced muscle growth, muscle strength, oxygen delivery and utilization (VO2Max). With BFRT, lighter loads can be used to build muscle while sparing the joints from heavy loading and without overly fatiguing the central nervous system. The objectives of BFRT are 1) to increase the effectiveness of physical therapy, 2) safely increase muscle mass, reduce arterial stiffness, increase bone density, increase Vo2Max, improve carotid arterial compliance and enhance response of the autonomic nervous system, 3) improve muscle endurance in 1/3 the time, improve strength and hypertrophy after surgery, improve muscle recruitment and increase anabolic growth signaling.

Conditions

Interventions

TypeNameDescription
OTHERBlood flow restriction trainingBFRT is done with 4 exercises with low load resistance of 30% 1 repetition maximum

Timeline

Start date
2020-04-14
Primary completion
2022-02-15
Completion
2022-02-15
First posted
2020-04-22
Last updated
2022-02-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04357184. Inclusion in this directory is not an endorsement.